CytomX Therapeutics (NASDAQ: CTMX) — Company Overview, News & Financial Data
CytomX Therapeutics develops innovative cancer treatments using Probody® Therapeutics to target cancer cells and reduce side effects.
CytomX Therapeutics
CytomX Therapeutics (NASDAQ:CTMX) specializes in creating innovative cancer treatments through its proprietary technology, Probody® Therapeutics. This unique approach focuses on developing treatments that are more selective in targeting cancer cells, potentially reducing side effects associated with traditional cancer therapies. Their portfolio includes exciting projects in various stages of development, aimed at treating a wide range of cancers. CytomX's objective is to harness the power of its platform to advance oncology medicine and improve the outcomes for patients facing this challenging disease. By targeting the unmet needs in cancer treatment, CytomX strives to bring pioneering therapies from the lab to the clinic.
Snapshot
Operations
Products and/or services of CytomX Therapeutics
- Probody therapeutics platform for enhancing antibody specificity and reducing toxicity.
- BMS-986249 and BMS-986288, Probody-based treatments targeting CTLA-4 for advanced solid tumors.
- CX-2029, a Probody drug conjugate aimed at CD71-expressing cancers.
- CX-2009, a first-in-class Probody drug conjugate targeting CD166 for patients with advanced solid tumors.
- Collaborations with industry leaders like Bristol-Myers Squibb and Pfizer to develop next-generation cancer immunotherapies.
- Research into utilizing Probody technology for non-oncology indications to broaden therapeutic applications.
CytomX Therapeutics executive team
- Sean A. McCarthyChairman & CEO
- Christopher W. OgdenSVP, CFO & Secretary
- Rachael LesterChief Business Officer & Senior VP
- Marcia P. BelvinSenior VP & Chief Scientific Officer
- Alejandra Veronica CarvajalChief Legal Officer
- Danielle Olander-MoghadassianSenior VP & Chief Human Resources Officer
- Leslie RobbinsSenior Vice President of Intellectual Property
- Yu-Waye ChuSenior VP & Chief Medical Officer
- Dawn BensonSenior Vice President of Quality & Product Manufacturing
- Stephanie RobertsonSenior Vice President of Alliances & Program Leadership
Latest news about CytomX Therapeutics
Key financials
Reported results for CytomX Therapeutics, in USD.
- Market cap
- 499M
- Revenue (TTM)
- 18.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.5
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 76.2M | -22.4M | -17.4M | |
| 138.1M | 25M | 31.9M | |
| 101.2M | -6.5M | -569K | |
| 53.2M | -101.3M | -97.3M |